No rules without exception: A long-term complete remission observed in a study using a LH-RH agonist in platinum-refractory ovarian cancer

European Journal of Cancer

Volumn 38, Issue SUPPL. 6, 2002, Pages

  Paskeviciute, L ^a,b   Roed, H ^a   Engelholm, A ^a  

^a FINSEN LABORATORY   (Denmark)

^b NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN RECEPTOR; LEUPRORELIN; PLATINUM;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 19244375104     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(02)00295-2     Document Type: Article

References (4)

1. Emons G., Schally A.V. The use of luteinizing hormone releazing hormone agonists and antagonists in gynecological cancers. Hum Reprod. 9:1994;176-194.
2. Imai A., Ohno T., Iida K., Fuseya T., Furui T., Tamaya T. Gonadotropin-releasing hormone receptor in gynecologic tumors. Cancer. 74:1994;2555-2561.
3. Simons W.E., Albrecht M., Hansel M., Dietl M., Holzel F. Cell line derived from human ovarian carcinomas. growth stimulation by gonadotropic and steroid hormones J Natl Cancer Inst. 70:1983;839-845.
4. Miyazaki M., Schally A.V., Nagy A.et al. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice. Am J Obstet Gynecol. 180:1999;1095-1103.